journal
MENU ▼
Read by QxMD icon Read
search

Critical Reviews in Oncology/hematology

journal
https://www.readbyqxmd.com/read/30196916/trastuzumab-uptake-in-her2-positive-breast-cancer-patients-a-systematic-review-and-meta-analysis-of-observational-studies
#1
REVIEW
Antony P Martin, Jennifer Downing, Madeleine Cochrane, Brendan Collins, Ben Francis, Alan Haycox, Ana Alfirevic, Munir Pirmohamed
Overexpression of the HER2 gene is predictive of treatment benefit with trastuzumab therapy for breast cancer (BC) patients. The study objective was to investigate whether all eligible patients with HER2-positive BC initiated trastuzumab therapy. A systematic search was conducted through PubMed, Web of Science PsycINFO, Cumulative Index to Nursing and Allied Health Literature (CINAHL) and Cochrane Library. From 2651 studies identified, 107 observational studies were included for full text review, of which 26 met the inclusion criteria and an additional 7 studies were identified through citation searching...
October 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30196915/clinical-update-on-k-ras-targeted-therapy-in-gastrointestinal-cancers
#2
REVIEW
Shubham Pant, Joleen Hubbard, Erika Martinelli, Tanios Bekaii-Saab
KRAS mutations are common in pancreatic and colorectal cancers and are associated with lack of response to anti-epidermal growth factor receptor therapy. Ras is an established therapeutic target that has long eluded efforts to develop specific inhibitors, while targeting downstream signaling pathways has proven largely ineffective, highlighting a need for rational combination strategies to overcome resistance. Recently, renewed interest in directly targeting Ras has led to the development of several small-molecule inhibitors that bind directly to K-Ras or its effector proteins, downregulation of K-Ras expression using therapeutic antisense oligonucleotides or siRNAs, and targeting scaffold proteins such as kinase suppressor of Ras...
October 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30196914/the-use-of-same-in-chemotherapy-induced-liver-injury
#3
REVIEW
B Vincenzi, A Russo, A Terenzio, A Galvano, D Santini, F Vorini, R Antonelli-Incalzi, U Vespasiani-Gentilucci, G Tonini
Drug-induced liver injury (DILI) remains the most common cause of acute liver failure in the Western world. Chemotherapy is one of the major class of drugs most frequently associated with idiosyncratic DILI. For this reason, patients who receive chemotherapy require careful assessment of liver function prior to treatment to determine which drugs may not be appropriate and which drug doses should be modified. S-adenosylmethionine (SAMe) is an endogenous agent derived from methionine. Its supplementation is effective in the treatment of liver disease, in particular intrahepatic cholestasis (IHC)...
October 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30196913/a-comprehensive-review-of-the-role-of-immune-checkpoint-inhibitors-in-brain-metastasis-of-renal-cell-carcinoma-origin
#4
REVIEW
Joseph Kattan, Elie El Rassy, Tarek Assi, Ziad Bakouny, Nicholas Pavlidis
The contribution of renal cell carcinoma (RCC) to brain metastases (BM) reaches 7-13%. These patients have limited survival with local control and targeted therapies. Immune checkpoint inhibitors (ICI) revolutionized the treatment landscape of RCC but commonly excluded BM patients from their pivotal trials. The daily clinical practice often imposes the use of ICI in RCC patients with BM in view of the promising survival times and durations of response. Only small prospective trials have included BM patients but rarely reported on the efficacy or safety of ICI in this subgroup...
October 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30196912/georcc-recommendations-on-target-volumes-in-radiotherapy-for-head-neck-cancer-of-unkown-primary
#5
REVIEW
Joaquín Cabrera Rodríguez, Jon Cacicedo, Jordi Giralt, Enrique García Miragall, Marta Lloret, Fernando Arias, María Angeles González Ruiz, Jorge Contreras
Head Neck Cancer of Unknown Primary (HNCUP) is a rare condition, representing approximately 5-10% of all head neck cancers. Radiotherapy, adjuvant or radical, is usually employed in the treatment of those patients. To date, no specific guidelines for the optimal definition of the target volume to be irradiated have been published. In recent years, there have been advances in the knowledge of the molecular biology of HNCUP, its diagnostic imaging and the implementation of sophisticated radiotherapy techniques with enhanced precision in target localization and treatment delivery...
October 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30196911/role-of-vena-cava-filters-for-the-management-of-cancer-related-venous-thromboembolism-systematic-review-and-meta-analysis
#6
REVIEW
Cristhiam Mauricio Rojas-Hernandez, James A Zapata-Copete, Herney Andrés García-Perdomo
BACKGROUND: Results from cohort studies evaluating the benefit in prevention of recurrent Venous Thromboembolism in cancer population are heterogeneous and controversial. OBJECTIVE: To determine the effectiveness and harms of vena cava filters alone or combined with anticoagulation to prevent the risk of recurrent venous thromboembolism in patients with cancer-related venous thromboembolism. MATERIALS AND METHODS: A search strategy was conducted in the MEDLINE, CENTRAL, EMBASE and LILACS databases...
October 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30196910/evolution-of-randomized-controlled-trials-and-surrogacy-of-progression-free-survival-in-advanced-metastatic-urothelial-cancer
#7
REVIEW
Fei Liang, Sheng Zhang, Qing Wang, Wenfeng Li
BACKGROUND: Clinical trials in advanced/metastatic urothelial cancer have been difficult to perform. We review the current characteristics of randomized controlled trials (RCTs) and evaluate whether PFS could be a potential surrogate endpoint for overall survival (OS) in advanced/metastatic urothelial cancer. METHODS: We identified trials by a systematic review of Medline, Embase, and the Cochrane Central Register of Controlled Trials from inception to April 2017...
October 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30196909/early-mortality-in-myeloma-patients-treated-with-first-generation-novel-agents-thalidomide-lenalidomide-bortezomib-at-diagnosis-a-pooled-analysis
#8
REVIEW
Sara Bringhen, Massimo Offidani, Salvatore Palmieri, Francesco Pisani, Rita Rizzi, Stefano Spada, Andrea Evangelista, Nicola Di Renzo, Pellegrino Musto, Magda Marcatti, Roberto Vallone, Sergio Storti, Annalisa Bernardini, Riccardo Centurioni, Enrico Aitini, Angelo Palmas, Ombretta Annibali, Emanuele Angelucci, Paola Ferrando, Anna Baraldi, Stefano Rocco, Alessandro Andriani, Agostina Siniscalchi, Valerio De Stefano, Vittorio Meneghini, Antonio Palumbo, Sara Grammatico, Mario Boccadoro, Alessandra Larocca
INTRODUCTION: Early toxic death (≤60 days of diagnosis) in elderly multiple myeloma (MM) patients is attributable to active disease, age and co-morbidities. Rate of early toxic deaths is 10% with conventional chemotherapy mainly due to infection and renal failure. Novel agents have improved MM outcome at the expense of newer toxicity. METHODS: We analyzed 1146 individual patient data to assess toxic deaths during induction treatment with first-generation novel agents thalidomide, lenalidomide, bortezomib...
October 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30196908/immuno-oncology-in-gi-tumours-clinical-evidence-and-emerging-trials-of-pd-1-pd-l1-antagonists
#9
REVIEW
Alexander Stein, Moehler Markus, Trojan Jörg, Goekkurt Eray, Arndt Vogel
The use of immune checkpoint inhibitors constitutes an emerging therapeutic field for the therapy of gastrointestinal (GI) malignancies following the recent FDA approvals of PD-1 inhibitors for esophago-gastric adenocarcinoma, hepatocellular carcinoma and for microsatellite-instable tumors, which are mainly colorectal cancers. This paper reviews the clinical evidence end of 2017 and discusses the clinical development programs of atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab in GI-tract cancers...
October 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30196907/biomarkers-of-response-to-immune-checkpoint-blockade-in-cancer-treatment
#10
REVIEW
Takeo Fujii, Aung Naing, Christian Rolfo, Joud Hajjar
Immune checkpoint inhibitors (ICPis) are emerging as the new corner stone of cancer treatment due to their ability to produce durable responses in patients with various cancers. But, objective responses to ICPis vary among each type of cancer. Further, treatment with ICPis is often associated with risk of developing immune-related adverse event, which are potentially life-threatening if untreated, indicating a need for patient selection. However, given the complexity of the tumor microenvironment and the dynamic interaction between tumor and immune cells, development of robust biomarkers to predict patients who are likely to respond to treatment with ICPis remains a challenge...
October 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30196906/the-changing-scenario-of-1-st-line-therapy-in-non-oncogene-addicted-nsclcs-in-the-era-of-immunotherapy
#11
REVIEW
A Russo, T Franchina, G R R Ricciardi, G Toscano, S Schifano, G Lo Certo, A Battaglia, E Pantò, M Scaffidi Fonti, V Adamo
During the last two decades front-line treatment of metastatic Non Small Cell Lung Cancer (NSCLC) has profoundly changed moving from the old "one size fits all" concept to a "histology-based" approach and then, for a small subgroup of patients to a "molecularly-selected" one. The development of immune checkpoint inhibitors and the unprecedented results reported in 2nd /3rd line prompted the evaluation of these novel therapeutic agents in chemotherapy-naïve patients either alone or in combination with platinum-based chemotherapy...
October 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30097241/ablative-stereotactic-radiotherapy-for-oligometastatic-colorectal-cancer-systematic-review
#12
REVIEW
J Kobiela, P Spychalski, G Marvaso, D Ciardo, V Dell'Acqua, F Kraja, A Błażyńska-Spychalska, A J Łachiński, A Surgo, R Glynne-Jones, B A Jereczek-Fossa
BACKGROUND: SBRT is a novel modality in treatment for oligometastatic colorectal cancer. We aimed to perform a systematic review of results of SBRT in maintaining LC (local control) for CRC liver and lung oligometastases. MATERIALS AND METHODS: The review was performed according to PRISMA and PICO guidelines. Database search using keywords: stereotactic, colon, colorectal, cancer, sbrt, sabr returned 457 results. 15 were included in the study. Only cohorts with CRC histology and reported LC were included...
September 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30097240/a-quick-scoping-review-of-efficacy-safety-economic-and-health-related-quality-of-life-outcomes-of-short-and-long-acting-erythropoiesis-stimulating-agents-in-the-treatment-of-chemotherapy-induced-anemia-and-chronic-kidney-disease-anemia
#13
REVIEW
Luiz H Arantes, Jeffrey Crawford, Pere Gascon, Mark Latymer, Vincent Launay-Vacher, Catherine Rolland, Florian Scotte, Jay Wish
Erythropoiesis-stimulating agents (ESAs) are man-made forms of erythropoietin used in the treatment of anemia. This quick-scoping review of systematic literature reviews (SLRs) was conducted to define the clinical, economic, and health-related quality of life (HRQoL) outcomes for short-acting and long-acting ESAs in patients with chronic kidney disease-induced anemia (CKD-IA) and patients with chemotherapy-induced anemia (CIA). Embase, Medline, and the Cochrane Database of Systematic Reviews were searched from their establishment until October 2017...
September 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30097239/do-sabr-related-toxicities-for-lung-cancer-depend-on-treatment-delivery
#14
REVIEW
Stamati Morias, Loredana Gabriela Marcu, Michala Short, Eileen Giles, Eva Bezak
Stereotactic ablative radiation therapy for lung cancer is an advanced technique where tumours are ablated with hypofractionated radiation doses, with a high degree of accuracy. The aim of this paper is to review the available literature and to discuss the SABR-induced toxicities for lung malignancies as a function of radiation delivery technique. A Medline search was conducted to identify the appropriate literature to fulfil the aim of this review and data from all applicable papers were collated and analysed...
September 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30097238/clinical-implication-of-changes-in-body-composition-and-weight-in-patients-with-early-stage-and-metastatic-breast-cancer
#15
REVIEW
Ilaria Trestini, Luisa Carbognin, Sara Monteverdi, Sara Zanelli, Alessandro De Toma, Clelia Bonaiuto, Rolando Nortilli, Elena Fiorio, Sara Pilotto, Massimo Di Maio, Antonio Gasbarrini, Giovanni Scambia, Giampaolo Tortora, Emilio Bria
Breast cancer represents the most frequent cancer among women in Western countries. Although physicians and patients have witnessed a significant evolution in both treatment strategies and personalized medicine (the identification of featured patients' subsets such as HER2-driven disease), the identification of additional prognostic clinical predictors referring to patients' dietary habits represents a research area aiming to further improve the overall management of this disease. In this regard, body composition (i...
September 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30097237/clinical-and-circulating-biomarkers-of-survival-and-recurrence-after-radiofrequency-ablation-in-patients-with-hepatocellular-carcinoma
#16
REVIEW
Matteo Canale, Paola Ulivi, Francesco Giuseppe Foschi, Emanuela Scarpi, Serena De Matteis, Gabriele Donati, Giorgio Ercolani, Mario Scartozzi, Luca Faloppi, Alessandro Passardi, Emiliano Tamburini, Martina Valgiusti, Giorgia Marisi, Giovanni Luca Frassineti, Andrea Casadei Gardini
Radiofrequency ablation (RFA) is an effective local treatment for curative intent in patients with cirrhosis of the liver and hepatocellular carcinoma (HCC) with diameter <3 cm. Several meta-analyses have shown that RFA and surgical resection are comparable in terms of their impact on overall survival. The only clinical data available on markers that are predictive of recurrence and survival after RFA treatment are based on retrospective observational studies. Prospective randomized trials are thus needed to further research in this area...
September 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30097236/immune-check-point-in-cervical-cancer
#17
REVIEW
F De Felice, C Marchetti, I Palaia, R Ostuni, L Muzii, V Tombolini, P Benedetti Panici
Despite different treatment strategies, locally advanced cervical cancer (CC) persists as one of the most incurable cancers among women worldwide. In fact, this setting of patients are at high risk of persistent and recurrent disease. In recent years, researches have investigated immune check-point inhibitors in hopes of determining improved response to therapy with prolongation of survival. We reviewed the published literature and conference proceedings and presented pivotal trials supporting immune check-point inhibitors use in the treatment of CC...
September 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30097235/immune-checkpoint-inhibitors-in-non-small-cell-lung-cancer-a-tool-to-improve-patients-selection
#18
REVIEW
Giuseppe Luigi Banna, Francesco Passiglia, Francesca Colonese, Stefania Canova, Jessica Menis, Alfredo Addeo, Antonio Russo, Diego Luigi Cortinovis
The identification of reliable predictive biomarkers of efficacy or resistance to immune-oncology (I-O) agents is a major issue for translational research and clinical practice. However, along with PDL1 and molecular features other clinical, radiological and laboratory factors can be considered for the selection of those patients who would not be the best candidate for immune-checkpoint inhibitors (ICPIs). We examined these factors, emerging from the results of currently available studies in non-small cell lung cancer (NSCLC), aiming to provide a useful and manageable tool which can help Oncologists in their everyday clinical practice...
September 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30097234/imaging-predictors-of-treatment-outcomes-in-rectal-cancer-an-overview
#19
REVIEW
Lakshmi Shree Mahadevan, James Zhong, BhanuPrasad Venkatesulu, Harmeet Kaur, Shreerang Bhide, Bruce Minsky, William Chu, Martijn Intven, Uulke A van der Heide, Baukelien van Triest, Sunil Krishnan, William Hall
The treatment protocols for rectal cancer continue to evolve, with increasing acceptance of a watch-and-wait policy for clinical complete responders to neoadjuvant chemoradiation therapy. It still, however, remains unclear who is likely to achieve a pathological complete response, which unequivocally portends a very favorable overall prognosis. Evolution of modern imaging techniques has paved the way for potential prediction of treatment response based on baseline, on-treatment, early post-treatment and subsequent follow-up imaging alone...
September 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30097233/critical-review-of-axillary-recurrence-in-early-breast-cancer
#20
REVIEW
Carlos A Castaneda, Pamela Rebaza, Miluska Castillo, Henry L Gomez, Miguel De La Cruz, Gabriela Calderon, Jorge Dunstan, Jose Manuel Cotrina, Julio Abugattas, Tatiana Vidaurre
Around 2% of early breast cancer cases treated with axillary lymph node dissection (ALND) underwent axillary recurrence (AR) and it has a deleterious effect in prognosis. Different scenarios have incorporated Sentinel Lymph Node (SLN) Biopsy (SLNB) instead of ALND as part of the standard treatment and more effective systemic treatment has also been incorporated in routine management after first curative surgery and after regional recurrence. However, there is concern about the effect of SLNB alone over AR risk and how to predict and treat AR...
September 2018: Critical Reviews in Oncology/hematology
journal
journal
20089
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"